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Recent  results  from  the phase  3 trial  of  RTS,S/AS01  malaria  vaccine  show  that  the  vaccine  induced  partial
protection  against  clinical  malaria  in  infants  and  children;  given  the  high  burden  of  the  disease  it  is cur-
rently  considered  for use  in  malaria  endemic  countries.  To  inform  adoption  decisions  the  paper  proposes
a generalizable  methodology  to  estimate  the  cost  of  vaccine  introduction  using  routinely  collected  and
publicly available  data  from  the  cMYP,  UNICEF,  and  WHO-CHOICE.  Costing  is carried  out  around  a set
of generic  activities,  assumptions,  and inputs  for delivery  of immunization  services  adapted  to a  given
country  and  deployment  modality  to capture  among  other  factors  the  structure  of the  EPI  program,  dis-
tribution  model,  geography,  and  demographics  particular  to  the  setting.  The  methodology  is  applied  to
estimate  the  cost  of RTS,S  introduction  in  Burkina  Faso,  Ghana,  Kenya,  Senegal,  Tanzania,  and  Uganda.  At
an assumed  vaccine  price  of  $5  per  dose  and  given  our  assumptions  on  coverage  and  deployment  strategy,
we estimate  total  economic  program  costs  for  a  6–9  months  cohort  within  $23.11–$28.28  per  fully  vacci-
nated  child  across  the  6 countries.  Net  of procurement,  costs  at country  level  are  substantial;  for  instance
in  Tanzania  these  could  add as  much  as  $4.2 million  per year  or an additional  $2.4  per infant  depending
on  the  level  of spare  capacity  in the system.  Differences  in  cost  of  vaccine  introduction  across  countries
are  primarily  driven  by  differences  in cost  of labour.  Overall  estimates  generated  with  the  methodology
result  in costs  within  the  ranges  reported  for  other  new  vaccines  introduced  in SSA  and  capture  multiple
sources  of  heterogeneity  in  costs  across  countries.  Further  validation  with  data  from  ﬁeld  trials  will  sup-
port use  of  the  methodology  while  also  serving  as  a  validation  for  cMYP  and WHO-CHOICE  as  resources
for  costing  health  interventions  in  the  region.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
RTS,S vaccine against Plasmodium falciparum malaria has
emonstrated moderate levels of efﬁcacy in phase 3 trials in Africa
nd is currently considered for use within the Expanded Pro-
ramme  on Immunization (EPI) in endemic countries [1]. Tested
n children (5–17 months) and young infants (6–12 weeks) the
accine has shown high initial efﬁcacy, but its protection waned
uickly with efﬁcacy against clinical disease at 36.3% and 25.9%
epending on age at immunization [2,3]. The vaccine is thus evalu-
ted as an additional tool for preventing clinical disease in children,
∗ Corresponding author at: Department of Epidemiology and Public Health, Swiss
ropical and Public Health Institute, Basel, Switzerland. Tel.: +41 612848706.
E-mail address: e.galactionova@unibas.ch (K. Galactionova).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.079
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
not a replacement for existing malaria preventive, diagnostic, and
treatment measures [4]. Despite being partially effective, modelling
studies predict RTS,S to have a substantial public health impact on
disease burden [5].
With a positive scientiﬁc opinion on vaccine efﬁcacy and safety
issued by the European Medicines Agency earlier this year, the
WHO  is expected to follow-up with a policy recommendation on
the use of RTS,S [4]. As countries, donors, and international orga-
nizations consider RTS,S introduction, data on program costs are
needed. Combined with effectiveness, cost data allow policy mak-
ers to assess the value of this new intervention in the context of a
malaria control strategy [6,7]. Decision-making at the country level
is further concerned with ﬁnancing and feasibility of mobilizing and
maintaining the level of resources to support the new vaccine [8,9].
To inform these decisions the study proposes a generalized
methodology to estimate costs of RTS,S introduction in the EPI
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rogram. We  apply it to assess these costs in Burkina Faso, Ghana,
enya, Senegal, Tanzania, and Uganda. Costing is implemented
round a set of generic and easily modiﬁable assumptions describ-
ng vaccine introduction; these capture among other factors the
tructure of the EPI program, distribution model, geography, and
emographics particular to the setting. Our ﬁndings illustrate the
road ranges for costs of introduction dependent on the level of
pare capacity to accommodate the vaccine. We  show that dif-
erences in EPI structure, cost of labour, and intensity of use of
esources within the system translate into signiﬁcant differentials
n cost of vaccine delivery between settings.
. Vaccine presentation and deployment strategy
We  base our assumptions about vaccine presentation on [10,11].
TS,S is a monovalent lyophilized vaccine reconstituted with an
djuvant; both require cold chain storage at 2–8◦ C. The vaccine and
he diluent are clipped together with a packed volume of 9.68 cm3
er two-vial package. Two doses per vial are yielded after reconsti-
ution.
Clinical trial data suggest that at least three doses are required
or protection against malaria. Following the trial design [11], we
valuate four immunization schedules: a program targeting infants
t 6, 10 and 12 weeks of age (6–12 weeks); children at 6, 7.5
nd 9 months (6–9 months); and a four dose schedule in the two
ge groups including vaccination at 18 months after the 3rd dose.
e  assume national roll-out to scale through routine outlets with
mmunization schedule tied to DTP. For 6–9 months implemen-
ation we assume ﬁrst and third doses to be administered along
ith vitamin A and measles vaccine and treat these as routine
mmunization visits for purposes of costing. New, out-of-routine
chedule, visits are assumed for the second dose in 6–9 months
nd fourth doses.
. Methods
.1. Perspective
A broad provider perspective is adopted in this evaluation; all
esources required to introduce the RTS,S into the national program
re included in the analysis.
.2. Scope
We  estimate both the economic and the ﬁnancial costs of
ntroducing the malaria vaccine into the EPI. Financial costs rep-
esent actual expenditures on goods and services. Economic costs
deﬁne costs in terms of the alternative uses that have been for-
one by using a resource in a particular way”; these include,
n addition to the ﬁnancial costs, a valuation of resources that
o not have ﬁnancial transactions (i.e. donated goods and ser-
ices or capital goods, health care resources diverted from other
ses or shared with other health programs, and inputs whose
rices are distorted [12]). Given paucity of data on the level of
xisting capacity in the system, the ﬁnancial costs are estimated
nder an assumption of 100% spare capacity to accommodate
he vaccine. In reality, however, some countries might need to
nvest in scaling-up across a range of service inputs be it cold
hain, vehicle ﬂeet, or labour to deliver the new intervention.
ssumptions for capacity scale-up, while not used to produce
stimates here, are shared in Supplementary File S1. The eco-
omic costs are implicitly evaluated under the assumption of no
pare capacity. Taken together, the two sets of estimates give
 wide but informative range for potential vaccine introduction
osts. 33 (2015) 6710–6718 6711
3.3. Assumptions for delivery of immunization services
We deﬁned a set of essential activities for RTS,S introduction
based on WHO  [7,13,14], USAID [15,16], and other guidelines on
immunization [17,18]. Assumptions about operational aspects of
the program were further informed by published micro-costing
studies that evaluated the introduction of new vaccines in low-
income countries [19–23]. No campaigns or additional outreach
activities outside of the routine EPI delivery were considered. For
deployment modalities requiring out-of-routine schedule visits
we assumed lower coverage rates and adjusted service deliv-
ery assumptions to reﬂect the longer time needed to administer
the vaccine, increased IEC, and supervision to maintain coverage.
Assumptions on activities costed and key inputs are presented
in detail in Table 1. Scenarios by schedule are highlighted in
Supplementary Table S1.
3.4. Resource lists
Resource lists were populated following the activities deﬁned
for vaccine introduction. These were adapted to countries
using comprehensive Multi-Year Plans (cMYP) for immunization
[24–29]. The latter were particularly useful in identifying staff cat-
egories, equipment, and quantities of resources used by the EPI
program at each level. Resource lists and prices for each country
are documented in Supplementary File S2.
3.5. Input prices and unit costs
Data on input prices and unit costs came from several sources.
Information on wages by level of EPI staff, per-diems, and some
other line items were taken from cMYP [24–29]. We  also used
data from the UNICEF [30] for prices of immunization supplies,
and related equipment. Additionally data from the WHO-CHOICE
databases were used to cost facility rental, hotel rates, fuel, and
other commodities [31]. Prices of commodities obtained from the
international price lists were adjusted for freight, insurance and
wastage [13].
Shared inputs were attributed to RTS,S based on the direct allo-
cation [12]; except for vaccinators whose contribution to the new
intervention was  costed based on time required to administer the
vaccine. Similarly, cost of cold chain and vehicles were allocated
to RTS,S based on use; for these inputs use refers to the volume
of the vaccine and immunization supplies and time for storage or
distance over which these were transported or stored.
Cost of capital items including vehicles, facilities, and equipment
was annualized over the respective estimated useful life. Expendi-
tures associated with activities held in the introductory stage were
considered capital goods and were annualized and discounted over
5 years at 3%.
3.6. Algorithm for calculating cost of immunization
For each activity outlined in Table 1 we  deﬁned formulas to com-
bine price and unit cost data with assumptions on resource use.
These start with the general representation of an activity in terms
of cost components, break it down to micro inputs and detail how
unit costs are combined with quantities to obtain total cost per
activity. Formulas are presented in Supplementary File S3; these
are generalized and could be adapted to alternate assumptions on
service delivery. Costs are estimated for a single cohort of surviving
infants and are reported in terms average annual, per FVC, and per
dose administered metrics.
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Table 1
Activities, assumptions, and inputs for delivery of immunization services.
Stage Program
component
Activity Activity assumptions Resource assumptions Economic costs Financial costs
Introduction Planning - Micro-planning
- Development of
training materials
- Development of EIC
materials
- Micro-planning at
central level assuming
a total of 1 month of
preparatory work
- 3 1-day workshops for
planning and
development of training
and IEC materials at
central level including
national and regional
EPI managers (2 from
each region)
- Wages
-  Per-diems
-  Hotel
-  Vehicle
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
-  Printed materials
- Facility rental
- Per-diems
-  Hotel
-  Vehicle
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
-  Printed materials
Cold store
assessment
- Inventory of cold
chain, assessment of
spare capacity for
introduction of new
vaccine
- Assessment
conducted by EPI cold
store staff
- Costed based on
estimates from cMYP
Cold store assessment
Revision of
immunization
cards and tally
sheets
- Revision of
immunization cards
and tally sheets to
include new vaccine
- Revised cards and
tally sheets printed for
the target cohort
- 25% reserve stock
- Full cost of revised
cards and tally sheets
printed for the target
cohort allocated to
RTS,S in the ﬁrst year,
thereafter a proportion
allocated to RTS,S
- Printing tally sheets
- Printing
immunization cards
- Printing tally sheets
- Printing
immunization cards
Training - Training of trainers
-  Training of regional
supervisors
-  Training of
immunization staff
- 5 day training of
trainers (2 nurses per
district) at central
level
- 2 day training
workshop for regional
supervisors at central
level
- 1 day training of
vaccinators at district
level (5 nurses from
regional and district
facilities; 1 from all
other levels)
- Start training the year
of vaccine introduction
- After ﬁrst year RTS,S
speciﬁc training
integrated into routine
EPI training for new
staff and refresher
courses
-  Wages
-  Per-diems
-  Hotel
-  Vehicle
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
-  Printed materials
- Facility rental
- Per-diems
-  Hotel
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
-  Printed materials
Social
Mobilization
and  IEC
- Launching ceremony
at central level
-  Sensitization
meetings at district
level
- TV advertisement
-  Radio advertisement
- Flyers and posters
-  Launching ceremony
including 5 speakers,
band, volunteers (1/50
attendees), technical
staff
- IEC meetings at
district level involving
regional EPI
ofﬁcers(1/district);
band, volunteers
- First year of program
roll-out, thereafter
integrated with routine
EPI IEC activities
- Wages
-  Per-diems
-  Speaker fees
- Band fees
- Volunteers
-  Hotel
-  Vehicle
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
-  Printed materials
- Facility rental
-  TV, radio
advertisement
-  Flyers, posters
- EPI per-diems
-  Speaker fees
- Band fees
- Hotel
-  Vehicle maintenance
and overheads
- Consumables
-  Stationaries
Printed materials
- TV, radio
advertisement
-  Flyers, posters
Recurrent Supervision - Supervision over
program
implementation
- EPI staff at central
and subnational levels
- Number of supervisory
visits and staff involved
in supervision of EPI
including drivers based
on cMYP records
-  Proportion of wages,
per-diems, transport
costs allocated to RTS,S
- Wages
-  Per-diems
-  Vehicle
-  Vehicle maintenance
and overheads
- For deployments
including doses
outside of routine
schedule include EPI
wages, per-diems,
transportation for the
increase in intensity of
supervision activities
Monitoring and
program
management
- Collecting data on
vaccine stock and
coverage
-  Strategic planning
Administrative
support
- Printing of
immunization cards
and tally sheets
-  Post introduction
evaluation
- NIP staff at central
and subnational EPI
levels
-  Post introduction
evaluation conducted
externally
- Proportion of EPI
wages allocated to RTS,S
-  Proportion of annual
printing costs allocated
to  RTS,S
- Post introduction
evaluation costed based
on  estimates from cMYP
-  Post introduction
evaluation annualized
over 5 years
- Wages
-  Tally sheets
- Immunization cards
-  Post introduction
evaluation
- Tally sheets
Immunization cards
- Post introduction
evaluation
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Table  1 (Continued)
Stage Program
component
Activity Activity assumptions Resource assumptions Economic costs Financial costs
Training - Refresher training
and training of new
staff
- Integrated into
routine EPI training
- Proportion of annual
EPI budget for training
allocated to RTS,S
- Proportion of annual
EPI budget for training
allocated to RTS,S
Social
Mobilization
and  IEC
- Social Mobilization
and IEC on RTS,S
- Integrated into
routine EPI Social
Mobilization and IEC
activities
-  Proportion of annual
EPI budget for Social
Mobilization and IEC
- Proportion of annual
EPI budget for Social
Mobilization and IEC
Procurement - Procurement of
vaccines and supplies
- Procurement of
vaccines and supplies
through the UNICEF
Supply Division
- Including freight and
insurance, wastage
- UNICEF procurement
and handling fee
- Vaccines
- Syringes
- Alcohol
- Cotton wool
-  Safety boxes
-  UNICEF handling fee
- Vaccines
-  Syringes
-  Alcohol
-  Cotton wool
-  Safety boxes
- UNICEF handling fee
Storage - Storage of vaccines
and immunization
supplies
- Type of cold store
equipment assigned
by administrative
level based on cold
and dry storage
volume required
- Storage costs
calculated based on
volume of vaccines and
supplies
- Months of storage
based on number of
deliveries at each level
- Wages
- Cold store equipment
- Equipment
maintenance,
overheads
- Facility
- Facility overheads
- Equipment
maintenance,
overheads
-  Facility overheads
Transportation - Transport of
vaccines and
immunization
supplies to
sub-national stores
and health facilities
- Type of vehicle by
administrative level
- Grossing factors by
level and type of
equipment used to
transport the vaccines
- Fuel, and maintenance
based on average
distance between
administrative units
- Transit costs scaled by
volume of the vaccine
and supplies to be
transported by delivery
route over vehicle
storage capacity of the
vehicle
- Wages
- Vehicle
- Vehicle maintenance
and overheads
- Cold boxes
- Vehicle maintenance
and overheads
- Cold boxes annual
replacement (20%)
Vaccination - Fixed site
vaccination
- Outreach
vaccination
- Vaccines
administered by
nurses
- Outreach from
facilities to remote
areas by nurses on
bikes
- 7 min  per dose when
administered alone;
5 min  when
administered with
another vaccine
- Outreach costed based
on number of days
conducting outreach
activities as per cMYP
Immunization ofﬁce of
20 m2
- Wages
- Per-diems
- Facility
- Facility overheads
- Furniture
- Stationaries
- Vaccine carrier
- Bicycle
- Facility overheads
-  Stationaries
Waste
management
-  Incineration of
syringes and vials
- Incinerator at
national, regional, and
district facilities
- Fire pit at lower level
health centers
- Wages
- Incinerator, bottle,
protective gear crusher
- Equipment
maintenance and
- Fuel
-Equipment
maintenance and
overheads
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c.7. Sensitivity analysis
The most critical assumptions made when estimating cost of
accine delivery relate to coverage, wastage rates, and use of labour
t service point. These parameters were varied over an inclusive
ange while keeping all other inputs at base values. Assumptions
n wastage, discount rate, and time to administer the vaccine were
eneric; country data were used in the baseline for all other inputs
aried. Resulting estimates of cost of vaccine delivery are summa-
ized by country in tornado plots.
. Results
.1. Overview of key demographic, coverage, and EPI inputs by
ountryDifferences in country cohorts and the EPI system detailed
n Table 2 help interpret the level and variation in costs across
ountries. The cohort size of Tanzania of 1.7 million infants is aboutoverheads
-  Bottle crusher
- Fuel
4 times as large as that of Senegal. There is variation not only in the
level of coverage achieved but also in the level of coverage sustained
between the doses. In Uganda coverage at third dose is 8 percentage
points lower than the ﬁrst dose; the drop-off is about 3 percentage
points in Ghana and Senegal. There is variation in wages at facil-
ity level: nearly $800 per month are reported for Kenya, $421 and
$115 per month for Tanzania and Burkina Faso, respectively. Inter-
estingly the ordering of countries changes when we look at wages
at higher levels of EPI; both at central and district levels highest
wages are reported for ofﬁcers in Ghana. Finally, there are differ-
ences in the number of days and number of EPI staff conducting
supervision visits across countries; these vary from 0.5 to about 10
days per month with as few as 4 to as many as 9 ofﬁcers per district
involved in supervisory capacity.
4.2. Cost of RTS,S immunizationUnless noted, costs are presented for the 6–9 months schedule
assuming a vaccine price per dose of $5; estimates for other imple-
mentation strategies are reported in Supplementary Tables S2–9.
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Table 2
Overview of key demographic, coverage, and EPI inputs by country.
Burkina Faso Ghana Kenya Senegal Tanzania Uganda
Number of surviving infants1 719′218 767′114 1′220′634 453′259 1′716′679 1′450′141
6–9  months coverage dose 12 71% 71% 62% 72% 74% 67%
6–9  months coverage dose 32 66% 68% 57% 69% 68% 59%
Wages  nurse $115 $263 $791 $565 $421 $216
Per-diems outreach nurse $10 $4 $27 $12 $11 $5
Days  outreach nurse 2.5 5 3 3 4 5
Wages  EPI manager central level $563 $2482 $2373 $1131 $1506 $705
Wages  EPI manager district level $428 $1880 $791 $1019 $948 $867
Per-diems EPI managers at district level $10 $26 $16 $17 $37 $11
Days  supervision EPI managers at district level 2 5 2 2–10 4–14 5–10
EPI  managers at district level conducting supervision 9 3 7 6 5 4
Source: Unless otherwise stated, estimates are extracted from country cMYP costing tool [24–29]; nominal values inﬂated to 2013 via US GDP deﬂator. 1CIA, The World Factbook
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d2013). Surviving infants. Retrieved from https://www.cia.gov/library/publications/
5%  of DTP. UNICEF, Child Health, Immunization (2013). Immunization Coverage by A
evision).
accine introduction costs expressed in terms of ﬁnancial cost per
nfant range between $0.76 and $1.72 (Table 3); these costs assume
n existing capacity and represent a minimum initial investment
eeded at country level to introduce the new antigen. Program costs
ncluding annualized introduction and annual recurrent costs range
rom about $21.71 to $22.86 per FVC in ﬁnancial terms; the range
or the economic costs is wider – from $23.11 to $28.28 per FVC
cross the 6 countries. Annual program costs increase with size of
he cohort; cost of procurement accounts for most of these expend-
tures: vaccines and immunization supplies make up about 95% of
nancial and 84% of economic costs.
.3. Differences in cost of RTS,S immunization by country
Country differences in cost of vaccine delivery are a function of
rogram design, coverage, EPI structure, number of antigens in the
PI schedule, and prices, the most critical of which is cost of labour.
he lowest economic cost of delivery is estimated for Burkina Faso
t $0.72 and highest for Kenya – at about $2.34 per dose adminis-
ered (Fig. 1 A). Over a three-fold difference between the countries
s largely driven by wage differentials: compared to Burkina Faso,
ages of EPI ofﬁcers in Kenya are nearly ﬁve times higher; the dif-
erentials persist across all distribution levels although at lower
evels wage differences are smaller (Table 2). In addition, compared
o other countries, Kenya has one of the lowest projected coverage
ates resulting in a lower denominator and, consequently, a lower
ase over which the ﬁxed costs, including introduction investment,
re allocated. When summarized in terms of economic cost per FVC,
ariation between countries is much smaller: the lowest estimate
s for Burkina Faso at $23.11 and the highest – for Kenya at $28.28
Fig. 1 B). Convergence in costs at this level is due to differences in
overage between countries; cost per FVC increases steeply with
rop-off between doses.
able 3
ummary of average annual costs of RTS,S immunization deployed via 6–9 months sched
Burkina Faso Ghana 
Introduction costs per surviving infant ﬁnanciala $1.04 $1.72 
Recurrent costs per dose administered ﬁnancialb $6.99 $7.01 
Total  ﬁnancial costs per FVC $21.82 $21.74 
Total  economic costs per FVC $23.11 $24.08 
Total  procurement costsc $9′903′660 $10′679′27
Total  ﬁnancial costs $10′361′365 $11′259′05
Total  economic costs $10′970′655 $12′469′92
a Total ﬁnancial cost of activities held in the introductory stage (micro-planning, cold ch
etails.
b Average annual ﬁnancial costs of running the program, net of introduction costs.
c Cost of vaccines, immunization equipment, and supplies.orld-factbook/; An assumption; coverage in 6–9 months schedule is taken to be
. Retrieved from: http://data.unicef.org/child-health/immunization (WUENIC, 2013
4.4. Differences in cost of RTS,S immunization by schedule
Differences in cost by schedule are similar across the 6 countries;
these are illustrated in Fig. 2 for Tanzania. For 6–12 weeks and
6–12 weeks 4 dose implementations, the cost of delivery is lowest;
higher costs are estimated for 6–9 months modalities, although at
this level differences between strategies are modest. When summa-
rized as cost per FVC, program costs for modalities including doses
outside of the routine schedule are signiﬁcantly higher. The much
higher cost per FVC for boosting schedules is again due to coverage
assumptions, namely we assumed 80% of 3rd dose coverage for 4th
dose, resulting in a lower denominator for these strategies.
4.5. Cost drivers of RTS,S immunization
Resource requirements for each program component as a pro-
portion of average annual delivery costs are illustrated in Fig. 3.
Costs at the facility level associated with the immunization visit
account for the largest proportion of total delivery costs. The rela-
tive weight of other inputs varies across settings with differences
across input categories mainly driven by differences in the struc-
ture of EPI program (levels of cold storage, number of staff at each
unit, etc.), resource use, and wages. For instance, in Kenya labour
heavy vaccination activities account for almost 60% of total deliv-
ery costs compared to only about 35% in Burkina Faso where, as
discussed, reported wages are signiﬁcantly lower. Activities such
as supervision, monitoring and introduction incorporate hetero-
geneities in wage structure across countries as well as levels of
resource use. The latter is illustrated with supervision activities; in
Tanzania supervision accounts for nearly 16% of total program costs
based on reported 4–14 days per month devoted to the activity
across EPI levels; in contrast, in Kenya and Burkina Faso an average
of only 3 days per months are allocated to supervision.
ule in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda (USD, 2013).
Kenya Senegal Tanzania Uganda
$1.58 $1.59 $0.97 $0.76
$7.17 $7.01 $6.92 $7.08
$22.63 $21.71 $21.81 $22.86
$28.28 $25.49 $24.62 $24.80
9 $14′591′719 $6′447′159 $24′677′812 $18′322′750
9 $15′741′310 $6′789′375 $25′551′472 $19′388′822
3 $19′674′652 $7′972′356 $28′846′864 $21′037′518
ain evaluation, training, etc.) without annualization or discounting. See Table 1 for
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sig. 1. Average annual economic cost of RTS,S immunization deployed via 6–9 mon
A)  Bars represent cost of vaccine delivery (program costs net of vaccine and immu
child  receiving full schedule) including vaccines, immunization supplies, and cost 
.6. Sensitivity analysis
Results of the sensitivity analysis show that cost of service deliv-
ry changes almost proportionally with immunization coverage
Fig. 4). These are sensitive to assumptions on time to administer
he vaccine both within and outside of the EPI schedule; if instead
f 5 min  to administer an additional vaccine dose [19,32] 15 min  are
equired, to allow, for instance, for information and incentivisation,
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A. Per dose administered, delivery
ig. 2. Average annual economic cost of RTS,S immunization in Tanzania by deployment m
f  vaccine and immunization supplies) per dose administered; (B) bars represent total pro
upplies, and cost of delivery.hedule in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda (USD, 2013).
on supplies) per dose administered; (B) bars represent total program cost per FVC
very.
service costs would increase by as much as 25%. Use of EPI shared
resources including cold chain, vehicles, and program management
are among other inﬂuential parameters.5. Discussion
Costing an intervention that has not been implemented is a dif-
ﬁcult undertaking further complicated by the absence of country
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Fig. 3. Distribution of average annual economic costs of RTS,S immunization deployed via 6–9 months schedule in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and
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tganda: Service delivery. Pie charts represent the distribution of cost of vaccine deli
ategory covers all costs incurred at point of delivery excluding vaccines and immu
olicy with respect to its use. This study presented an approach to
stimate the prospective costs of RTS,S introduction that can be eas-
ly adapted to the speciﬁcs of the vaccine presentation, country EPI
rogram, and implementation strategy. One of the main advantages
f the methodology is that it can be implemented using routinely
ollected and publicly available.
Estimates presented should be interpreted in the context of
ssumptions made on vaccine price, coverage, delivery modality,
nd data constraints. While we made every attempt to adapt these
o country settings, lack of detail on operational aspects of the pro-
ram might have resulted in a more normative distribution model.
side from concerns about relevance of activities costed for a given
etting, more general concerns about the quality of cMYP reports,
orrowing of data and extrapolation across countries to ﬁll in the
ata gaps introduced additional uncertainty.
One previous study assessed prospective costs of RTS,S intro-
uction via routine EPI in Tanzania [19]; these were estimated
sing a similar methodology and relying on local data including
ystem capacity use. The incremental cost of vaccine introduction
as estimated at $0.66 per dose, which is lower than $0.93 per dose
stimated in our study for Tanzania, but comparable given differ-
nces in scope. The contribution of the main cost drivers to the
accine delivery costs were of the same order of magnitude in the
wo studies. Consistent with these earlier analyses, delivery costsprogram costs net of vaccine and immunization supplies) by activity; “Vaccination”
on supplies.
account only for a small proportion of total program costs. At a vac-
cine price of $5 per dose about 95% of ﬁnancial and 84% of economic
costs are accounted for by vaccines and immunization supplies.
Although comparability with other antigens is limited given
differences in vaccine properties, deployment strategies, immu-
nization rate, etc., costs estimated here for RTS,S delivery are
similar to other vaccines recently introduced in the region. De
la Hoz-Restrepo [33] cited non-vaccine costs associated with the
introduction of rotavirus and pneumococcal conjugate vaccines
in developing countries at $0.74 (IQR:$0.58–$1.32) and $1.27
(IQR:$0.99–$1.37) per dose, respectively. Grifﬁth [20] estimated
the incremental cost of introducing DTwP-hepatitis B-Hib vaccine
in Ethiopia at $1.15 per FVC. The estimate is closest in scope to
ﬁnancial vaccine delivery costs presented in this study – $0.90 to
$1.91 per FVC across the 6 countries. Klinger et al. [34] reported
cost per an additional birth dose of Hepatitis B in Mozambique
at $1.46 ($1.27–$2.27). Hutubessy et al. [21] presented costs for
HPV introduction in Tanzania using a similar methodology; the
deployment strategy for the vaccine required reaching older chil-
dren outside of the routine EPI delivery schedule with estimated
costs of delivery ranging from $1.36 per dose for ﬁnancial to $3.56
for economic costs. While these ﬁndings are yet to be replicated,
we note that costs reported here are tied to explicit assumptions
on vaccine deployment including labour; as countries decide on
K. Galactionova et al. / Vaccine 33 (2015) 6710–6718 6717
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Fig. 4. One-way sensitivity analysis on average annual economic cost of RTS,S immunization deployed via 6–9 months schedule in Burkina Faso, Ghana, Kenya, Senegal,
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Discount rate” values of 0% and 10% are evaluated.
he operational strategy for RTS,S introduction estimates could be
evised accordingly.
Costs estimated by the study are of interest to a diverse set
f stakeholders. At country level these provide baseline values of
esources required to introduce and maintain the intervention.
nformation particularly vital for Gavi graduating countries that
ill assess not only the additional resource needs for the new
ntigen but also the increased cost-sharing for provision of immu-
ization for the current schedule and sustainability of the new
chedule in the longer term. We  show that delivery costs at coun-
ry level are substantial; for instance, in Tanzania these could range
etween $0.8 and $4.1 million per year depending on scope of cost-
ng and level of spare capacity in the system.
For donors and global institutions supporting immunization
rograms the analysis presents some initial estimates of resource
eeds for vaccine introduction; moreover it highlights the extent
f resource use beyond procurement supplied by countries when
ntroducing the intervention. Donors, in particular Gavi, might be
nterested in the cost of particular program components like vac-
ine introduction investment to gauge the size of introduction
rants to support RTS,S in endemic countries. We  show that the
osts are higher in particular if vaccine is delivered outside of
outine schedule and if new visits would be required. For the 6ly. “Days outreach” under low scenario are set to 2 and to 15 under high scenario.
countries, we  estimate introduction costs between $0.76 and $1.72
per infant in the surviving cohort; these are comparable to levels of
support currently awarded by Gavi for new vaccine introduction:
$0.80 per child for vaccines delivered to infants and $2.40 per girl
for HPV vaccine [35].
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